TOKYO -- Takeda Pharmaceutical has suspended the development of a plasma therapy for COVID-19 after it failed to show effectiveness in clinical trials, according to a Tuesday disclosure to investors.
Japan's top drugmaker, along with U.S.-based CSL Behring and other members of the CoVIg-19 Plasma Alliance, had been working on a new treatment for the coronavirus using antibodies taken from the plasma of recovered patients.
